The clinical phase of the Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS) will be completed by the end of April as scheduled. The last patient scheduled to complete their last study visit on 19 April.
The Company continues to receive a high level of interest from the majority of patients who have already completed the trial and who want post-study access to MIS416.
Lets hope for the SPSM sufferers that it can change their way of living and from a SH view for a big Pharma to buy IIL over.
The clinical phase of the Phase 2B trial of MIS416 in patients...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.59M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.5¢ | 14.5¢ | $78.75K | 518.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3340 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 97318 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| ATX (ASX) Chart |